The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC).
 
James J. Harding
Consulting or Advisory Role - Adaptimmune; Bristol Myers Squibb Foundation; CytomX Therapeutics; Eisai; Exelixis; Imvax; Merck; QED Therapeutics; Zymeworks
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GenoScience Pharma (Inst); Incyte (Inst); Lilly (Inst); Loxo/Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polaris (Inst); Yiviva (Inst); Zymeworks (Inst)
 
Hooman Yarmohammadi
No Relationships to Disclose
 
Kim Anna Reiss
Honoraria - MJH Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology; GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Tesaro (Inst)
 
Joanne F. Chou
No Relationships to Disclose
 
Marinela Capanu
No Relationships to Disclose
 
Richard K. G. Do
Honoraria - ALK (I); Genentech (I)
Consulting or Advisory Role - DBV Technologies (I)
Patents, Royalties, Other Intellectual Property - UptoDate chapters on Food Allergy (I)
 
Danny Khalil
No Relationships to Disclose
 
Imane H. El Dika
Honoraria - Lynx Group
Consulting or Advisory Role - QED Therapeutics
Travel, Accommodations, Expenses - QED Therapeutics
 
Christine S. Ferrer
No Relationships to Disclose
 
Olivia Heffernan
No Relationships to Disclose
 
J Daniel Giardina
No Relationships to Disclose
 
Taha Merghoub
Stock and Other Ownership Interests - Imvaq therapeutics
Honoraria - Leap Therapeutics; Pfizer
Consulting or Advisory Role - ImmunoGenesis; Immunos Therapeutics
Research Funding - Bristol-Myers Squibb; Surface Oncology
Patents, Royalties, Other Intellectual Property - inventor on patent applications related to work on oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modeling, CD40, GITR, OX40, PD-1 and CTLA-4.
 
William R. Jarnagin
No Relationships to Disclose
 
Gregory Nadolski
No Relationships to Disclose
 
Joseph Patrick Erinjeri
No Relationships to Disclose
 
Michael C. Soulen
Consulting or Advisory Role - Genentech; Guerbet; Instylla
Research Funding - BTG; Guerbet
 
Benjamin R. Tan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Merck Serono (Inst); Roche/Genentech (Inst); Sillajen (Inst); tyrogenex (Inst)
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Adicet Bio; Alnylam; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene (I); Center for Emerging & Neglected Diseases (CEND) (I); CytomX Therapeutics (I); Eisai; Exelixis; Flatiron Health; Genoscience Pharma; Helio Health; Incyte; Ipsen; Legend Biotech; Lilly (I); Merck Serono; Nerviano Medical Sciences; QED Therapeutics; Rafael Pharmaceuticals (I); RedHill Biopharma; Roche/Genentech; SERVIER; Silenseed (I); Sillajen; SOBI (I); Surface Oncology; TheraBionic; twoXAR; Vector Health; Yiviva; Yiviva
Research Funding - Agios (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Bayer (Inst); BioNtech (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Flatiron Health (Inst); Genentech/Roche (Inst); Genoscience Pharma (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Silenseed (Inst); Yiviva (Inst)
Travel, Accommodations, Expenses - Polaris